[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-455163-105":59,"doc-detail-455163-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","pembrolizumab-induced-tubulointerstitial-nephritis-in-early-stage-triple-negative-breast-cancer-a-case-report","Pembrolizumab-Induced Tubulointerstitial Nephritis in Early-Stage Triple-Negative Breast Cancer - A Case Report","","Immunotherapy is integral to modern cancer care, and immune checkpoint inhibitors (ICIs) are used across tumor types, including early-stage triple-negative breast cancer. ICIs can also cause immune-related adverse events (irAEs) affecting multiple organ systems. This case report describes acute tubulointerstitial nephritis (ATIN) due to pembrolizumab in a woman in her 50s after neoadjuvant chemoimmunotherapy, presenting with acute kidney injury and inflammatory marker elevation. Infectious and obstructive causes were excluded; biopsy supported ATIN, and corticosteroids produced rapid improvement and near-complete renal recovery, emphasizing early recognition and prompt management.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pembrolizumab-induced-tubulointerstitial-nephritis-in-early-stage-triple-negative-breast-cancer-a-case-report/455163/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pembrolizumab-induced-tubulointerstitial-nephritis-in-early-stage-triple-negative-breast-cancer-a-case-report/455163.png","ImageObject",300,407,{"name":92,"@type":93},"Rainbow Cat","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-30",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What immune-related adverse event is described in this case report?","Question",{"text":112,"@type":113},"The report describes acute tubulointerstitial nephritis (ATIN) as an immune-related adverse event associated with pembrolizumab.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What clinical changes led clinicians to suspect acute kidney injury?",{"text":117,"@type":113},"After three cycles of neoadjuvant chemotherapy combined with pembrolizumab, the patient developed acute kidney injury (AKI) with elevated inflammatory markers, prompting further evaluation.",{"name":119,"@type":110,"acceptedAnswer":120},"How was the suspected pembrolizumab-induced kidney injury treated and how did the patient respond?",{"text":121,"@type":113},"Pembrolizumab was discontinued, and corticosteroid therapy with prednisolone 0.5 mg/kg/day was started, leading to rapid improvement and near-complete recovery of renal function.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},455163,1790792518,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":4},962090769181,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Review began 11/11/2025  \nReview ended 12/04/2025  \nPublished 12/08/2025  \n© Copyright 2025  \nFerreira et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0. , which permits unrestricted use , distribution , and reproduction in any medium , provided the original author and source are credited.  \nDOI: 10.7759/cureus.98726  \nOpen Access Case Report  \nPembrolizumab-Induced Tubulointerstitial Nephritis in Early-Stage Triple-Negative Breast Cancer: A Case Report  \nCatarina Ferreira 1 , Cristiana H. Martins 1, Renata Carvalho 2, Roberto Silva 3, Jorge Rodrigues 1  \n1. Medical Oncology, Braga Local Health Unit, Braga, PRT 2. Nephrology, Braga Local Health Unit, Braga, PRT 3. Pathology, Unilabs, Porto, PRT  \nCorresponding author: Catarina Ferreira, [catarinadamaiaferreira@gmail.com](catarinadamaiaferreira@gmail.com)  \nAbstract  \nImmunotherapy has become an integral part of cancer treatment, with immune checkpoint inhibitors (ICIs) increasingly used across multiple tumor types, including early-stage triple-negative breast cancer. However, these therapies can trigger immune-related adverse events (irAEs) that may involve various organ systems. We report a case of acute tubulointerstitial nephritis (ATIN) secondary to pembrolizumab in a woman in her 50s treated for early-stage triple-negative breast cancer. After three cycles of neoadjuvant chemotherapy combined with pembrolizumab, the patient presented with acute kidney injury (AKI) and elevated inflammatory markers. Infectious, obstructive, and other secondary causes were excluded. A kidney biopsy was performed, with findings consistent with ATIN, most likely pembrolizumab-induced. Pembrolizumab was discontinued, and corticosteroid therapy (prednisolone 0.5 mg/kg/day) led to rapid improvement and near-complete recovery of renal function. This case highlights the importance of early recognition and prompt management of ICI-related AKI to prevent irreversible kidney damage.  \nCategories: Pharmacology, Nephrology, Oncology  \nKeywords: acute tubulointerstitial nephritis, early-stage triple-negative breast cancer, immune checkpoint inhibitors, immune-related adverse events, pembrolizumab  \nIntroduction  \nImmunotherapy represents a significant advancement in the development of novel cancer treatments. Of the various immunotherapeutic approaches, immune checkpoint inhibitors (ICIs) have transformed the management of multiple malignancies, demonstrating substantial clinical benefits and improved patient  \noutcomes in recent years [1] . In the KEYNOTE-522 trial, the addition of pembrolizumab, a humanized  \nmonoclonal antibody that targets programmed cell death protein 1 (PD-1) and exhibits antitumor  \nproperties, to neoadjuvant chemotherapy, followed by adjuvant pembrolizumab administration, demonstrated significant improvements in pathological complete response rates and overall survival among patients with early-stage triple-negative breast cancer, while maintaining an acceptable safety profile [2-4].  \nBased on these findings, the integration of pembrolizumab into chemotherapy regimens as first-line therapy in the neoadjuvant setting for early-stage triple-negative breast cancer has become standard practice.  \nDespite its clinical benefit, the administration of pembrolizumab is associated with a broad range of  \nimmune-related adverse events (irAEs), most commonly affecting the gastrointestinal, dermatologic, and endocrine systems. Although renal toxicity is an uncommon side effect that was not identified in initial studies, it warrants clinical vigilance given its potential severity and risk of irreversibility. In fact, renal irAEs continue to be underreported, despite being clinically significant due to their potential severity and the risk associated with delayed diagnosis [1,5] . There is also limited research on ICI-related AKI in early  \nstage triple-negative breast cancer.  \nWe present a case of ICI-related AKI, manifes","cbCaiqiWH3KIXxpO","https://ap.wps.com/l/cbCaiqiWH3KIXxpO","pdf",3352828,"English","# Abstract\n# Introduction\n# Case Presentation","[{\"question\":\"What immune-related adverse event is described in this case report?\",\"answer\":\"The report describes acute tubulointerstitial nephritis (ATIN) as an immune-related adverse event associated with pembrolizumab.\"},{\"question\":\"What clinical changes led clinicians to suspect acute kidney injury?\",\"answer\":\"After three cycles of neoadjuvant chemotherapy combined with pembrolizumab, the patient developed acute kidney injury (AKI) with elevated inflammatory markers, prompting further evaluation.\"},{\"question\":\"How was the suspected pembrolizumab-induced kidney injury treated and how did the patient respond?\",\"answer\":\"Pembrolizumab was discontinued, and corticosteroid therapy with prednisolone 0.5 mg/kg/day was started, leading to rapid improvement and near-complete recovery of renal function.\"}]","Pembrolizumab-Induced Tubulointerstitial Nephritis in Early-Stage Triple-Negative Breast Cancer - A Case Report | PDF",1790742238,18]